Isofol Medical AB
- Biotech or pharma, therapeutic R&D
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of chemotherapy-based standard treatment regimens for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is high. A phase Ib/II study is now being conducted with an optimized dosing regimen that is expected to further improve the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}